Short Interest in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Declines By 16.3%

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) saw a large decline in short interest during the month of May. As of May 31st, there was short interest totalling 8,200 shares, a decline of 16.3% from the May 15th total of 9,800 shares. Based on an average trading volume of 12,200 shares, the short-interest ratio is presently 0.7 days.

Institutional Investors Weigh In On Calliditas Therapeutics AB (publ)

A hedge fund recently bought a new stake in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. acquired a new position in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 980 shares of the company’s stock, valued at approximately $25,000. 2.83% of the stock is owned by institutional investors and hedge funds.

Calliditas Therapeutics AB (publ) Trading Down 0.8 %

Calliditas Therapeutics AB (publ) stock traded down $0.30 during mid-day trading on Friday, hitting $38.77. The company’s stock had a trading volume of 4,268 shares, compared to its average volume of 30,741. The company has a debt-to-equity ratio of 8.46, a current ratio of 2.69 and a quick ratio of 2.62. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of -20.96 and a beta of 1.78. The business has a 50 day moving average price of $25.64 and a 200-day moving average price of $23.37. Calliditas Therapeutics AB has a 12 month low of $15.25 and a 12 month high of $41.90.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last issued its quarterly earnings data on Thursday, May 23rd. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.74). The firm had revenue of $28.43 million for the quarter, compared to the consensus estimate of $35.78 million. Calliditas Therapeutics AB (publ) had a negative net margin of 40.19% and a negative return on equity of 160.87%. As a group, analysts forecast that Calliditas Therapeutics AB will post -0.86 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Lifesci Capital downgraded shares of Calliditas Therapeutics AB (publ) from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 28th. Stifel Nicolaus reaffirmed a “hold” rating and set a $40.00 price objective (down from $55.00) on shares of Calliditas Therapeutics AB (publ) in a report on Tuesday, May 28th. Citigroup reaffirmed a “neutral” rating and set a $39.00 price objective on shares of Calliditas Therapeutics AB (publ) in a report on Friday, May 31st. Jefferies Financial Group reissued a “hold” rating and issued a $39.00 price target (down from $58.00) on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th. Finally, HC Wainwright reissued a “neutral” rating and issued a $39.00 price target on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th. Six research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $35.00.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.